Active Biotech AB
BTPC
Company Profile
Business description
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
Contact
Scheelevagen 22
P.O. Box 724
Lund223 63
SWET: +46 46192000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Our view after CBA shares plunge
Steady profit, but rising risks and rich valuation give pause.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,853.50 | 12.90 | -0.15% |
| CAC 40 | 8,007.97 | 28.05 | 0.35% |
| DAX 40 | 24,136.81 | 181.88 | 0.76% |
| Dow JONES (US) | 49,693.20 | 67.36 | -0.14% |
| FTSE 100 | 10,325.35 | 60.03 | 0.58% |
| HKSE | 26,488.36 | 99.92 | 0.38% |
| NASDAQ | 26,402.34 | 314.14 | 1.20% |
| Nikkei 225 | 63,354.51 | 82.40 | 0.13% |
| NZX 50 Index | 13,005.49 | 57.57 | -0.44% |
| S&P 500 | 7,444.25 | 43.29 | 0.58% |
| S&P/ASX 200 | 8,609.80 | 4.90 | -0.06% |
| SSE Composite Index | 4,199.19 | 43.38 | -1.02% |